Amalgamated Bank Purchases New Holdings in PTC Therapeutics, Inc. (PTCT)
Amalgamated Bank purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 6,632 shares of the biopharmaceutical company’s stock, valued at approximately $228,000.
Other hedge funds also recently bought and sold shares of the company. Pacer Advisors Inc. acquired a new stake in PTC Therapeutics in the third quarter valued at approximately $300,000. Boston Advisors LLC lifted its stake in PTC Therapeutics by 9.1% in the fourth quarter. Boston Advisors LLC now owns 27,375 shares of the biopharmaceutical company’s stock valued at $940,000 after acquiring an additional 2,285 shares during the last quarter. BlackRock Inc. lifted its stake in PTC Therapeutics by 5.4% in the third quarter. BlackRock Inc. now owns 3,639,709 shares of the biopharmaceutical company’s stock valued at $171,067,000 after acquiring an additional 187,548 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in PTC Therapeutics in the third quarter valued at approximately $4,178,000. Finally, Canton Hathaway LLC lifted its stake in PTC Therapeutics by 57.1% in the fourth quarter. Canton Hathaway LLC now owns 1,100 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 400 shares during the last quarter. Institutional investors and hedge funds own 84.26% of the company’s stock.
In other news, insider Christine Marie Utter sold 28,709 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $34.97, for a total value of $1,003,953.73. Following the transaction, the insider now owns 5,937 shares of the company’s stock, valued at $207,616.89. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Michael Schmertzler purchased 66,225 shares of the company’s stock in a transaction dated Friday, January 25th. The stock was purchased at an average cost of $30.20 per share, for a total transaction of $1,999,995.00. Following the transaction, the director now owns 86,766 shares of the company’s stock, valued at $2,620,333.20. The disclosure for this purchase can be found here. Company insiders own 7.50% of the company’s stock.
NASDAQ:PTCT opened at $38.35 on Tuesday. PTC Therapeutics, Inc. has a 12 month low of $25.10 and a 12 month high of $52.95. The company has a market capitalization of $2.19 billion, a PE ratio of -20.84 and a beta of 2.07. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.83 and a current ratio of 1.92.
PTC Therapeutics Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.
Featured Article: Key terms to understand channel trading
Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.